Terkko Navigator / Journal of Cystic Fibrosis

Association between stool consistency and clinical variables among infants with cystic fibrosis: Findings from the BONUS study

Dose adjustments of Elexacaftor/Tezacaftor/Ivacaftor in response to mental health side effects in adults with cystic fibrosis

Research letter: The impact of elexacaftor/tezacaftor/ivacaftor on adherence to nebulized maintenance therapies in people with cystic fibrosis

Rapid chloride and bicarbonate determination by capillary electrophoresis for confirmatory testing of cystic fibrosis infants with volume-limited sweat specimens

CFTR dysfunction and targeted therapies: A vision from non-cystic fibrosis bronchiectasis and COPD

Caution advised in the use of CFTR modulator treatment for individuals harboring specific CFTR variants

Pathological remodeling of distal lung matrix in end-stage cystic fibrosis patients

Clinical outcomes of a large cohort of individuals with the F508del/5T;TG12 CFTR genotype

Association between early respiratory viral infections and structural lung disease in infants with cystic fibrosis

Early Pseudomonas aeruginosa predicts poorer pulmonary function in preschool children with cystic fibrosis

Staphylococcus aureus detection from CF respiratory samples is improved using alternative media

Priority areas in the assessment and treatment of CF exacerbations: Location, duration, inflammation

Use of elexacaftor/tezacaftor/ivacaftor among cystic fibrosis lung transplant recipients

Antipseudomonal treatment decisions during CF exacerbation management

Ways of coping and survival in Cystic Fibrosis: a 20-year longitudinal study

Onset of systemic arterial hypertension after initiation of elexacaftor/tezacaftor/ivacaftor in adults with cystic fibrosis: A case series

Current prices versus minimum costs of production for CFTR modulators

A new era has dawned for persons with cystic fibrosis; however many knowledge gaps exist in our efforts to improve care

Mucus and mucus flake composition and abundance reflect inflammatory and infection status in cystic fibrosis

Immunogenicity of the COVID-19 BNT162b2 vaccine in adolescents and young adults with cystic fibrosis

Constipation and cystic fibrosis. Slow movement

A case report of CFTR modulator administration via carrier mother to treat meconium ileus in a F508del homozygous fetus

Re: Impact of spiroware re-analysis method on multiple-breath washout outcomes in children with cystic fibrosis; M.A. Oestreich, F. Wyler, P. Latzin et al.

Magnetic resonance imaging detects improvements of pulmonary and paranasal sinus abnormalities in response to elexacaftor/tezacaftor/ivacaftor therapy in adults with cystic fibrosis

Obesity in Cystic fibrosis: prevalence, trends and associated factors data from the US cystic fibrosis foundation patient registry

Club cell secretory protein and lung function in children with cystic fibrosis

Global access to affordable CFTR modulator drugs: Time for action!

Factors in childhood associated with lung function decline to adolescence in cystic fibrosis

Elexacaftor-Tezacaftor- Ivacaftor improves sinonasal outcomes in cystic fibrosis

Health care costs in a randomized trial of antimicrobial duration among cystic fibrosis patients with pulmonary exacerbations

A year in review: Real world evidence, functional monitoring and emerging therapeutics in 2021

Interleukin-1 beta is a potential mediator of airway nitric oxide deficiency in cystic fibrosis

Impact of azithromycin on serum inflammatory markers in children with cystic fibrosis and new Pseudomonas

Net benefit of ivacaftor during prolonged tezacaftor/elexacaftor exposure in vitro

Ethmoidal mucocele causing proptosis in a pediatric patient with cystic fibrosis: A case report

AZD5634, an inhaled ENaC inhibitor, in healthy subjects and patients with cystic fibrosis

Testicular cancer in men with cystic fibrosis

THE CLINICAL IMPACT OF THE COVID-19 PANDEMIC FIRST WAVE ON PATIENTS WITH CYSTIC FIBROSIS IN NEW YORK1]

Expression of cystic fibrosis lung disease modifier genes in human airway models

A Phase 3, open-label, 96-week trial to study the safety, tolerability, and efficacy of tezacaftor/ivacaftor in children ≥ 6 years of age homozygous for F508del or heterozygous for F508del and a residual function CFTR variant

How the sweat gland reveals levels of CFTR activity

Safety of mRNA-based vaccines against SARS-CoV-2 in people with cystic fibrosis aged 12 years and over

Parenthood impacts short-term health outcomes in people with cystic fibrosis

Clinical outcomes in cystic fibrosis at 6 years of age with tricare insurance coverage

Men's sexual and reproductive health in cystic fibrosis in the era of highly effective modulator therapies–A qualitative study

CFTR modulator therapy alters plasma sphingolipid profiles in people with cystic fibrosis

Hypervitaminosis A with fulminant secondary intracranial hypertension following personalized medicine-based Elexacaftor/Tezacaftor/Ivacaftor initiation in a preadolescent with cystic fibrosis

Worldwide rates of diagnosis and effective treatment for cystic fibrosis

Sustained effectiveness of elexacaftor-tezacaftor-ivacaftor in lung transplant candidates with cystic fibrosis

Forskolin induced swelling (FIS) assay in intestinal organoids to guide eligibility for compassionate use treatment in a CF patient with a rare genotype